文献速递瓣膜外科

低风险患者外科主动脉瓣置换术后的生存率:当代试验基准

Survival After Surgical Aortic Valve Replacement in Low-Risk Patients: A Contemporary Trial Benchmark.
PubMed 文献 · Ann Thorac Surg · 2023-10-17

基于STS数据库2011至2019年42,586例符合PARTNER 3和Evolut低风险试验标准的初次孤立SAVR患者,8年全因死亡率为12.4%,5年生存率为92.9%。生存率在STS预测死亡风险更低、年龄更轻、左心室射血分数更高的患者中显著更优。

要点

  • 符合低风险试验标准的SAVR患者8年全因死亡率为12.4%。
  • STS预测死亡风险低于1%或年龄低于75岁时,8年生存率达95%。
  • 生存率随STS预测死亡风险降低、年龄减轻、左心室射血分数升高而显著改善(P < .001)。

核心结论

  • 这项全国性研究证实SAVR术后长期生存率仍然优异,5年生存率为92.9%,可为低手术风险患者的临床决策提供参考。

研究设计与样本

  • 回顾性分析STS数据库2011至2019年间所有初次孤立SAVR患者,研究人群42,586例符合PARTNER 3和Evolut低风险随机试验的纳入/排除标准,并按STS预测死亡风险、年龄和左心室射血分数分层,主要终点为全国死亡索引全因死亡率。

主要发现

  • 平均年龄74.3 ± 5.7岁,平均STS预测死亡风险1.9% ± 0.8%。
  • Kaplan-Meier分析显示全因死亡率在1年、3年、5年和8年分别为2.6%、4.5%、7.1%和12.4%。
  • 亚组分析中,较低STS预测死亡风险(P < .001)、较年轻年龄(P < .001)和较高左心室射血分数(P < .001)的患者生存率显著更优。
  • 当STS预测死亡风险低于1%或患者年龄低于75岁时,SAVR术后8年生存率为95%。

关键数值与推荐

  • 研究人群符合PARTNER 3和Evolut低风险随机试验的纳入/排除标准。
  • 按STS预测死亡风险、年龄和左心室射血分数进行分层分析。
  • 主要终点为全国死亡索引全因死亡率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of transcatheter aortic valve replacement for severe aortic stenosis in low-risk patients necessitates an evaluation of contemporary long-term, real-world outcomes of similar patients undergoing surgical aortic valve replacement (SAVR) in a national cohort. METHODS: All patients undergoing primary, isolated SAVR in The Society of Thoracic Surgeons (STS) database between 2011 and 2019 were examined. The study population of 42,586 adhered to the inclusion/exclusion criteria of the Placement of Aortic Transcatheter Valves (PARTNER) 3 and Evolut Low Risk randomized trials. Patients were further stratified by STS predicted risk of mortality (PROM), age, and left ventricular ejection fraction. The primary end-point was all-cause National Death Index mortality. Unadjusted survival to 8 years was estimated using the Kaplan-Meier method. RESULTS: Mean age was 74.3 ± 5.7 years and mean STS PROM was 1.9% ± 0.8%. The overall Kaplan-Meier time to event analysis for all-cause mortality at 1, 3, 5, and 8 years was 2.6%, 4.5%, 7.1%, and 12.4%, respectively. In subset analyses, survival was significantly better for (1) lower STS PROM (P < .001), (2) younger vs older age (P < .001), and (3) higher vs lower left ventricular ejection fraction (P < .001). When STS PROM was below 1% or the patient age was below age 75 years, the 8-year survival after SAVR was 95%. CONCLUSIONS: The results of this national study confirm that long-term survival after SAVR remains excellent, at 92.9% at 5 years. These contemporary longitudinal data serve to aid in the balanced interpretation of current and future trials comparing SAVR and transcatheter aortic valve replacement and may assist in the clinical decision-making process for patients of lower surgical risk.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Thourani VH, Habib R, Szeto WY, et al. Survival After Surgical Aortic Valve Replacement in Low-Risk Patients: A Contemporary Trial Benchmark. Ann Thorac Surg. 2023. PMID: 37858882. doi:10.1016/j.athoracsur.2023.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。